Ninlaro (ixazomib) is an oral anticancer treatment option for multiple myeloma. It’s taken by mouth once a week during the first 3 weeks of a 4-week treatment cycle. This medication is typically taken as a triplet therapy along with lenalidomide (Revlimid) and dexamethasone. But this treatment is only prescribed for people who've already tried other medication options for multiple myeloma. Ninlaro (ixazomib) can cause stomach problems, like nausea, diarrhea, and constipation), which can be serious.
Ninlaro (ixazomib) is a type of targeted therapy known as a proteasome inhibitor. It works by blocking a group of proteins, called proteasomes, inside cancer cells. Typically, proteasomes help cells break down proteins that they no longer need. When Ninlaro (ixazomib) blocks proteasomes from working, cell waste builds up, which causes cancer cells to die.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Please note: The side effects above were reported by people in clinical trials who also took lenalidomide (Revlimid) and dexamethasone.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
You should take Ninlaro (ixazomib) as instructed by your provider. This medication is usually given on certain days during each cancer treatment cycle, so it’s important to follow the schedule your provider gives you. How long you receive Ninlaro (ixazomib) treatment depends on several factors, including how well the medication is working to treat your cancer, your specific anticancer regimen, and how well you tolerate it. Don’t stop taking Ninlaro (ixazomib) without first discussing it with your provider.
There are currently 3 FDA-approved proteasome inhibitors to treat multiple myeloma: Ninlaro (ixazomib), bortezomib (Velcade), and Kyprolis (carfilzomib). All 3 medications are typically given in combination with other medications for multiple myeloma. But there are some differences between them. One main difference is that Ninlaro (ixazomib) is taken by mouth, while Kyprolis (carfilzomib) and bortezomib (Velcade) are given as injections. Your provider might choose one proteasome inhibitors over another for you based on certain factors, such as what other treatments you've already received and what other health issues you might have. Talk with your provider if you want to discuss the the options most appropriate for you.
Ninlaro (ixazomib) is only FDA-approved for people who've already tried at least one other anticancer treatment regimen for multiple myeloma. Ask your provider whether Ninlaro (ixazomib) is a possible option for you.
If you experience nausea or vomiting from Ninlaro (ixazomib), let your provider know. They can help you figure out the next steps, depending on your symptoms are and your personal preferences. For example, your provider can suggest ways to minimize nausea or vomiting through lifestyle changes, such as eating foods that are more bland or eating smaller meals more often throughout the day. Your provider can also prescribe anti-nausea medications for you if appropriate. If you're vomiting frequently and losing a lot of body fluid, they'll recommend that you drink enough water or fluids to stay hydrated and to minimize loss of important electrolytes. And in cases of severe vomiting, your provider might ask you to go to the hospital for more medical care.
It isn’t known if Ninlaro (ixazomib) can pass into breast milk, but there’s a risk of serious harm to nursing infants if it does. Because of this risk, you shouldn’t breastfeed during Ninlaro (ixazomib) treatment or for at least 3 months after your last dose. Talk with your provider if you have any questions about breastfeeding or other ways to feed your baby while receiving Ninlaro (ixazomib) or after treatment.
Ninlaro (ixazomib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Ninlaro (ixazomib) can lower your platelet levels and put you at higher risk of bleeding or bruising. Low platelet count is typically seen during week 2 to 3 of each 4-week treatment cycle. If your platelet level drops too low, you might need a platelet transfusion. Your provider will closely monitor your blood cell counts through routine lab work at least monthly while you’re receiving Ninlaro (ixazomib). Let your provider know as soon as possible if you experience bleeding and bruising that doesn’t stop or go away, because you might need your dose lowered or your next dose delayed.
Ninlaro (ixazomib) can cause various stomach problems, like diarrhea, constipation, and nausea. These conditions can be serious because they can lead to dangerously low fluid or electrolyte levels (dehydration) and other medical problems. Let your provider know if you experience any of these problems. They might be able to prescribe anti-diarrhea or anti-nausea medications for you to ease your symptoms. If your problems are severe, your provider might need to stop your Ninlaro (ixazomib) treatment.
Ninlaro (ixazomib) can cause new or worsening nerve problems in your arms, hands, legs, and feet (peripheral neuropathy). These problems are typically mild. If you do experience symptoms of peripheral neuropathy, your provider might need to lower your dose of Ninlaro (ixazomib). Let your provider know if you experience numbness, pain, burning, a feeling of "pins and needles," or weakness in your arms or legs.
Some people taking Ninlaro (ixazomib) experienced swelling of their arms and legs. While this side effect can become severe, it was typically mild for most people in clinical trials. Let your provider know if you experience swelling of your arms or legs, or weight gain due to swelling. They might lower your Ninlaro (ixazomib) dose or adjust your dose of steroid.
Ninlaro (ixazomib) can cause rash in some people. Typically, the rashes aren’t severe. But there have been reports of very serious skin rash. Tell your provider right away if you experience a new or worsening rash, severe blistering or peeling of your skin, or mouth sores. If skin reactions occur, your provider might lower your dose of Ninlaro (ixazomib) or stop your treatment altogether, depending on how serious your skin reaction is.
Though rare, some people receiving Ninlaro (ixazomib) have experienced serious blood clots in the smallest blood vessels, including those in the kidney and brain. Let your provider know right away if you experience a fever, bruising, nose bleed, tiredness, or needing to urinate less often. You might have to stop treatment with Ninlaro (ixazomib) while your provider figures out the cause.
Rarely, Ninlaro (ixazomib) caused liver damage in people taking the medication. This can happen to anyone, but be sure to tell your provider if you have liver problems before starting this medication. Your provider will monitor your liver’s health through lab work while you’re taking Ninlaro (ixazomib) and might adjust your dose as needed. Let your provider know right away if you experience tiredness, loss of appetite, nausea or vomiting, dark urine, stomach pain, or yellowing of the eyes or skin, as these can be signs of liver problems.
Ninlaro (ixazomib) hasn’t been studied in human pregnancies, but animal studies show that it can cause harm to an unborn baby. If you're a female of childbearing age taking Ninlaro (ixazomib), your provider might check to see if you’re pregnant before you start treatment. If you’re female who’s s able to become pregnant or a male with a female partner with childbearing potential, use non-hormonal birth control (e.g., condoms) while you’re receiving Ninlaro (ixazomib) and for at least 3 months after your last dose. Let your provider know right away if you become pregnant during this time.
Ninlaro (ixazomib) is typically taken along with lenalidomide (Revlimid) and dexamethasone.
The typical starting dose is to take 4 mg of Ninlaro (ixazomib) by mouth once a week during the first 3 weeks (on days 1, 8, and 15) of a 4-week treatment cycle.
Your dose of Ninlaro (ixazomib) might be different if you're taking other medications that might interact with Ninlaro (ixazomib), or have liver or kidney problems.